Cargando…

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

To predict the public health impact on cervical disease by introducing human papillomavirus (HPV) vaccination in the United Kingdom, we developed a mathematical model that can be used to reflect the impact of vaccination in different countries with existing screening programmes. Its use is discussed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohli, M, Ferko, N, Martin, A, Franco, E L, Jenkins, D, Gallivan, S, Sherlaw-Johnson, C, Drummond, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360200/ https://www.ncbi.nlm.nih.gov/pubmed/17146475 http://dx.doi.org/10.1038/sj.bjc.6603501

Ejemplares similares

Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK
por: Cuzick, J, et al.
Publicado: (2010)

Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination
por: Pimenta, Jeanne M, et al.
Publicado: (2013)

Human papillomavirus infection in women who develop high-grade cervical intraepithelial neoplasia or cervical cancer: a case–control study in the UK
por: Grainge, M J, et al.
Publicado: (2005)

An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme
por: Sherlaw-Johnson, C, et al.
Publicado: (2004)

High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine
por: Hooi, Desiree J, et al.
Publicado: (2018)

Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study
por: Hibbitts, S, et al.
Publicado: (2008)

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica
por: Wang, S S, et al.
Publicado: (2003)

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial
por: Ramanakumar, Agnihotram V, et al.
Publicado: (2016)

Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen‐detected cervical precancer
por: Inturrisi, Federica, et al.
Publicado: (2020)

Differences in the risk of cervical cancer and human papillomavirus infection by education level
por: Franceschi, S, et al.
Publicado: (2009)

Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia
por: Pärna, Kersti, et al.
Publicado: (2023)

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
por: Clifford, G M, et al.
Publicado: (2003)

Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
por: Burger, E A, et al.
Publicado: (2012)

Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing
por: van Rosmalen, J, et al.
Publicado: (2012)

Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya
por: De Vuyst, H, et al.
Publicado: (2012)

Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays
por: Rebolj, Matejka, et al.
Publicado: (2016)

Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland
por: Leinonen, M K, et al.
Publicado: (2013)

High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders
por: Lam, J U H, et al.
Publicado: (2018)

Sexual behavior and infection with cervical human papillomavirus types 16 and 18
por: Itarat, Yuwadee, et al.
Publicado: (2019)

HPV16 genetic variation and the development of cervical cancer worldwide
por: Cornet, I, et al.
Publicado: (2013)

Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening
por: Bulkmans, N W J, et al.
Publicado: (2005)

Cervical cancer screening programmes and policies in 18 European countries
por: Anttila, A, et al.
Publicado: (2004)

Cervical human papillomavirus and HIV infection in women of child-bearing age in Abidjan, Côte d’Ivoire, 2010
por: Jaquet, A, et al.
Publicado: (2012)

Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica
por: Wang, S S, et al.
Publicado: (2004)

Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology
por: Wall, S R, et al.
Publicado: (2005)

Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening
por: Huh, Warner K., et al.
Publicado: (2014)

Benefit of cervical screening at different ages: evidence from the UK audit of screening histories
por: Sasieni, P, et al.
Publicado: (2003)

Estimating the asbestos-related lung cancer burden from mesothelioma mortality
por: McCormack, V, et al.
Publicado: (2012)

The predicted effect of changes in cervical screening practice in the UK: results from a modelling study
por: Canfell, K, et al.
Publicado: (2004)

Comparison of human papillomavirus‐based cervical cancer screening strategies in Tanzania among women with and without HIV
por: Kahesa, Crispin, et al.
Publicado: (2022)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Effect of multiple risk behaviours in adolescence on educational attainment at age 16 years: a UK birth cohort study
por: Wright, Caroline, et al.
Publicado: (2018)

Variability in the burden of disease estimates with or without age weighting and discounting: a methodological study
por: Egunsola, Oluwaseun, et al.
Publicado: (2019)

Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer
por: de Araújo Catão Zampronha, Rossana, et al.
Publicado: (2013)

Prevalence of Human Papillomavirus subtypes 16 and 18 among Yemeni Patients with Cervical Cancer
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2017)

Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up
por: Jensen, K E, et al.
Publicado: (2013)

Estimating the current and future cancer burden in Canada: methodological framework of the Canadian population attributable risk of cancer (ComPARe) study
por: Brenner, Darren R, et al.
Publicado: (2018)

Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa
por: Clifford, Gary M., et al.
Publicado: (2016)

Role of human papillomavirus status after conization for high‐grade cervical intraepithelial neoplasia
por: Huang, Huei‐Jean, et al.
Publicado: (2020)

Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case–control study
por: Landy, Rebecca, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hkuj5og09evio981hder83a2fe